Trinity Capital – a leading provider of diversified financial solutions to growth-stage companies – recently announced the commitment of $25 million in growth capital to Neuros Medical, a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life.
Neuros Medical’s Altius System integrates the company’s patented platform technology, On-Demand Bioelectric Nerve Block – which patients initiate as needed for targeted pain relief. And the technology blocks sensory nerves and has the potential to alleviate pain in nearly one million Americans with phantom limb and residual limb pain, fulfilling a significant need for patients. This system has the potential to reduce drug dependency as existing treatment options are primarily limited to opioids and gabapentinoids.
The growth capital is going to enable Neuros Medical to augment the recent equity raised and further scale operations to assist with their commercial launch.
KEY QUOTES:
“We are proud to partner with Neuros Medical on their journey to improve the lives of those suffering from chronic post-amputation pain, and we look forward to working with their team to support their continued growth.”
— Rob Lake, Senior Managing Director, Life Sciences at Trinity
“We appreciate the conviction Trinity has in the Neuros mission and our ability to scale commercialization, delivering this life-changing therapy to a large, underserved amputee population in desperate need of pain relief.”
— David Veino, President and Chief Executive Officer of Neuros Medical
